Department of Pharmacy, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, Shandong, P.R. China.
BMC Pharmacol Toxicol. 2022 Aug 10;23(1):62. doi: 10.1186/s40360-022-00603-4.
Cutaneous adverse drug reaction (CADR) is a common problem in clinical medication. This study aimed to investigate the correlation between clinical drug application and CADR occurrence as evidence for preventive strategies and rational clinical drug use.
We analyzed the characteristics of CADRs of 858 patients admitted to Shandong Provincial Third Hospital from March 2007 to December 2018. The most significant drugs concerning the common skin symptoms and their significance to CADR were investigated by case-non-case and multiple logistic regression analyses.
A total of 266 drugs were involved in 858 cases of CADR. Among the ten most relevant medications, primarily antibiotics and herbal injections, and nutritional support drugs, potassium sodium dehydroandrographolide succinate injection, and cefoperazone sodium and sulbactam sodium injection were found to be 2.1 and 1.45 times statistically more prone to CADRs than to other adverse drug reactions (ADRs), respectively. The main route of administration was intravenous (63.16%), with oral administration accounting for 25.19%. There were 747 cases of ADR, 71 of severe ADR, 2 of new and severe ADRs, and 38 cases of new ADR. Overall, 100 cases of CADR exhibited abnormal alanine aminotransferase, aspartate aminotransferase, and serum creatinine levels. The predictive factors for severe CADR occurrence included allergy and smoking histories, cefoperazone sodium, sulbactam sodium injection, levofloxacin lactate and sodium chloride injection.
Drug-induced CADR symptoms are commonly associated with other ARDs, predominantly rashes and pruritus, and are often accompanied by some medical conditions, especially liver and kidney damage. Detailed attention to a patient's primary diseases, allergy history, and drug safety profile could help prevent or reverse CADR in most patients.
皮肤不良反应(CADR)是临床用药中的常见问题。本研究旨在探讨临床用药与 CADR 发生的相关性,为预防策略和合理临床用药提供依据。
分析 2007 年 3 月至 2018 年 12 月山东省立第三医院收治的 858 例 CADR 患者的特点,采用病例对照和多因素 logistic 回归分析方法,探讨常见皮肤症状相关的最显著药物及其与 CADR 的相关性。
共涉及 858 例 CADR 患者 266 种药物。十种最相关药物中,以抗生素和中药注射剂、营养支持药物为主,穿心莲内酯琥珀酸脱氢钾、头孢哌酮钠舒巴坦钠注射剂分别比其他药物更易发生 CADR,风险比为 2.1 和 1.45。主要给药途径为静脉给药(63.16%),口服给药占 25.19%。发生 ADR747 例,其中严重 ADR71 例,新的严重 ADR2 例,新的 ADR38 例。共有 100 例 CADR 出现丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、血清肌酐异常。严重 CADR 发生的预测因素包括过敏史、吸烟史、头孢哌酮钠舒巴坦钠、乳酸左氧氟沙星氯化钠、注射用。
药物引起的 CADR 症状常与其他 ARD 相关,以皮疹和瘙痒为主,常伴有某些医学状况,特别是肝肾功能损害。详细关注患者的主要疾病、过敏史和药物安全性特征,有助于预防或逆转大多数患者的 CADR。